Reference health
Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
33/33 checkable references clean · checked 2026-07-25
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 33 checked references that resolve
resolves10.1182/blood.V99.5.1536
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis
resolves10.1182/blood-2002-03-0704
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia---results of the prospective multicenter LALA-94 trial
resolves10.1200/JCO.2000.18.3.547
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
resolves10.1182/blood.V97.6.1572
Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome
resolves10.1038/nm0596-561
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
resolves10.1056/NEJM200104053441402
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
resolves10.1182/blood-2001-12-0181
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
resolves10.1182/blood-2003-01-0154
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib
resolves10.1182/blood.V104.11.2738.2738
Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).
resolves10.1182/blood-2004-04-1389
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
resolves10.1182/blood.V104.11.4483.4483
Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate.
resolves10.1182/blood.V104.11.685.685
Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).
resolves10.1182/blood.V104.11.2739.2739
Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201.
resolves10.1182/blood.V104.11.2741.2741
Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.
resolves10.1182/blood.V104.11.2742.2742
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly with Imatinib Mesylate (STI571) and Chemotherapy. an Interim Analysis of the GRAALL AFR09 Trial.
resolves10.1182/blood-2004-09-3785
The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia
resolves10.1080/10428190310001625755
Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia
resolves10.1038/sj.leu.2402889
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back
resolves10.1182/blood-2002-06-1756
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia
resolves10.1182/blood.V89.7.2602
Detection of bcr-abl Transcripts in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia After Marrow Transplantation
resolves10.1038/sj.leu.2402729
Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190BCR-ABL-positive acute lymphoblastic leukemia
resolves10.1038/sj.leu.2403093
Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon-α (IFN-α) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
resolves10.1016/S0889-8588(05)70204-5
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
resolves10.1038/sj.leu.2402770
Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
resolves10.1016/j.ccr.2005.01.007
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
resolves10.1182/blood.V104.11.22.22
A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).
resolves10.1182/blood.V104.11.20.20
Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.
resolves10.1182/blood.V100.3.1068
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
resolves10.1038/sj.onc.1205724
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
The 7 references without a DOI — listed, not checked
no DOI — not checkedNowell PC, Hungerford D. A minute chromosome in human chronic granulocytic leukemias. Science. 1960;14:97.
no DOI — not checkedHoelzer D, Gökbuget N. Treatment of elderly patients with acute lymphoblastic leukemia. ASCO Education Book, 41st Annual Meeting May 13–17, 2005:533–539.
no DOI — not checkedMartin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. Advances in the treatment of adult acute lymphocytic leukemia, Hematol/ Oncol Clin North Am. 2001;15:97–120.
no DOI — not checkedMartin H, Atta J, Klein SA, et al. Autologous BMT/PBSCT in 40 patients with bcr-abl positive acute lymphoblastic leukemia: long-term follow-up of a GMALL study [abstract]. Hematology. 2001;I:187.
no DOI — not checkedOttmann OG, Wassmann B, Gökbuget N, et al. A randomized phase II study comparing Imatinib with chemotherapy as induction therapy in elderly patients with newly diagnosed Philadelphia-positive acute lymphoid leukemias (Ph+ALL) [abstract]. Hematology J. 2004;5:S112.
no DOI — not checkedPfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system (CNS) leukemia in patients with Philadelphia chromosome positive (Ph+) acute leukemias treated with imatinib mesylate (GlivecTM). Clin Cancer Res. 2003;9:4674–4681.
no DOI — not checkedWassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplant imatinib determines outcome in MRD-positive Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood First Edition Paper, prepublished online April 7, 2005; Blood-2004-05-1746.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-25 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1182/asheducation-2005.1.118"><img src="https://citestamp.com/citestamped/10.1182/asheducation-2005.1.118/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1182/asheducation-2005.1.118)